PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lerodalcibep→

Lerodalcibep PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2250073-78-8
Molecular formula
C3427H5324N908O1045S40
Molecular weight
77247.08 g/mol
Drug class
PCSK9 inhibitorrecombinant fusion protein lipid-lowering biologic
Mechanism of action
Binds proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity and prevents PCSK9 binding to hepatic LDL receptors, reducing receptor degradation and increasing LDL-receptor availability to clear LDL cholesterol from the blood.
Indications / reported uses
  • Adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, under the US FDA LEROCHOL indication (approved 12 December 2025)

Sources: US FDA prescribing information — LEROCHOL, revised August 2026 · NLM DailyMed — LEROCHOL (lerodalcibep-liga) · FDA Drug Trials Snapshot — LEROCHOL · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Lerodalcibep PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lerodalcibep Permitted Daily Exposure (PDE) report (the Lerodalcibep PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lerodalcibep Occupational Exposure Limit (OEL) report (the Lerodalcibep OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.